SARCOMA & RARE CANCERS
Real-world data has become integral to sarcoma research
Researchers’ confidence is growing, but the quality of the data generated may still represent a challenge
Telemedicine reduces delays in bone sarcoma management in rural India
A model implemented by a non-profit organisation exemplifies how virtual consultation and follow-up of patients with rare cancer can facilitate continuity of care
Long-term nirogacestat shows sustained benefits in desmoid tumours
Newly presented phase III trial and real-world findings reassure on the use of the gamma secretase inhibitor
TARGETED THERAPIES
Machine learning models predict adverse events and survival in patients receiving immunotherapy
New data supports the use of artificial intelligence for the administration of immune-check inhibitors in solid tumours
Talazoparib plus axitinib show some signs of efficacy in heavily pretreated cancers
Early-phase findings report manageable toxicity when combining the PARP inhibitor with the anti-angiogenesis inhibitor in two cohorts of patients with ovarian and castration-resistant prostate tumours
Trastuzumab deruxtecan shows encouraging overall response rates in untreated HER2-positive metastatic breast cancer
Results from an interim analysis suggest the antibody–drug conjugate alone or in combination with pertuzumab may have a role in the first-line setting
COLUMNS
Hypofractionation may help reduce the impact of radiotherapy on the environment
Recent research suggests a substantial reduction in greenhouse gas emissions with de-escalation per cancer patient
Innovation means progress for all people with cancer
Effectiveness, applicability and accessibility measure the value of novel technologies and therapies in oncology
The expanding toolbox for immuno-oncology
Novel treatment approaches show encouraging early results in solid tumours, but ways to boost precision immunotherapy are needed
OPINIONS
Tumour-agnostic drug development is revolutionising precision oncology
Vivek Subbiah
Novel insights into combination therapy in metastatic castration-resistant prostate cancer
Christoph Oing
ctDNA and beyond to serve immunotherapy
Umberto Malapelle
Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Christian Blank
Preventing the rise in obesity-related cancers in Asia
Elick Narayan
OPINIONS
Tumour-agnostic drug development is revolutionising precision oncology
Vivek Subbiah
Novel insights into combination therapy in metastatic castration-resistant prostate cancer
Christoph Oing
ctDNA and beyond to serve immunotherapy
Umberto Malapelle
Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Christian Blank
Preventing the rise in obesity-related cancers in Asia
Elick Narayan